ATNM Actinium Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ATNM

Price (delayed)

$6.67

Market cap

$196.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$121.51M

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application ...

Highlights
The debt has decreased by 18% YoY and by 4.4% from the previous quarter
ATNM's net income is down by 48% year-on-year but it is up by 2.6% since the previous quarter
The EPS has contracted by 34% YoY but it has grown by 5% from the previous quarter
ATNM's gross profit has dropped by 92% year-on-year
ATNM's revenue has dropped by 92% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Peers: BLUE KMDA ADXS

Key stats

What are the main financial stats of ATNM
Market
Shares outstanding
29.4M
Market cap
$196.07M
Enterprise value
$121.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.03
Price to sales (P/S)
2,190.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,500.12
Earnings
Revenue
$81,000
EBIT
-$48.82M
EBITDA
-$48.03M
Free cash flow
-$47.49M
Per share
EPS
-$1.83
Free cash flow per share
-$1.78
Book value per share
$1.33
Revenue per share
$0
TBVPS
$3.06
Balance sheet
Total assets
$81.45M
Total liabilities
$45.07M
Debt
$2.11M
Equity
$36.38M
Working capital
$69.77M
Liquidity
Debt to equity
0.06
Current ratio
9.21
Quick ratio
9.03
Net debt/EBITDA
1.55
Margins
EBITDA margin
-59,293.8%
Gross margin
100%
Net margin
-60,269.1%
Operating margin
-64,098.8%
Efficiency
Return on assets
-52.6%
Return on equity
-102.6%
Return on invested capital
-35,247.7%
Return on capital employed
-66.9%
Return on sales
-60,269.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
-8%
1 week
-26.62%
1 month
1.99%
1 year
-28.28%
YTD
31.3%
QTD
-14.81%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$81,000
Gross profit
$81,000
Operating income
-$51.92M
Net income
-$48.82M
Gross margin
100%
Net margin
-60,269.1%
ATNM's gross profit has dropped by 92% year-on-year
ATNM's revenue has dropped by 92% year-on-year
The operating income has dropped by 52% year-on-year
ATNM's net income is down by 48% year-on-year but it is up by 2.6% since the previous quarter

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.03
P/S
2,190.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,500.12
The EPS has contracted by 34% YoY but it has grown by 5% from the previous quarter
The price to book (P/B) is 48% higher than the 5-year quarterly average of 3.4 and 29% higher than the last 4 quarters average of 3.9
The equity has declined by 45% year-on-year and by 17% since the previous quarter
ATNM's revenue has dropped by 92% year-on-year

Efficiency

How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity has dropped by 121% year-on-year and by 13% since the previous quarter
The company's return on assets has shrunk by 70% YoY and by 6% QoQ

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 81% more than its total liabilities
Actinium Pharmaceuticals's total assets has decreased by 29% YoY and by 8% from the previous quarter
The quick ratio has decreased by 12% YoY and by 6% from the previous quarter
The debt is 94% less than the equity
The company's debt to equity has surged by 50% YoY and by 20% QoQ
The equity has declined by 45% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.